VASOPRESSOR AGENTS IN SEPTIC SHOCK



Similar documents
Septic Shock: Pharmacologic Agents for Hemodynamic Support. Nathan E Cope, PharmD PGY2 Critical Care Pharmacy Resident

Vasopressors. Judith Hellman, M.D. Associate Professor Anesthesia and Perioperative Care University of California, San Francisco

What is the Future of Epinephrine in Cardiac Arrest? Pros and Cons

The article is issued in the form of presentation presented at symposium

Inotropes/Vasoactive Agents Hina N. Patel, Pharm.D., BCPS Cathy Lawson, Pharm.D., BCPS

Fundamentals of Critical Care: Hemodynamics, Monitoring, Shock

Medical Direction and Practices Board WHITE PAPER

Dr Kenneth Tan. MBBS MMed(Anaes) MRCP(UK) EDIC FCCP Anesthesia and Intensive Care Services Mount Elizabeth Hospital

CENTER FOR DRUG EVALUATION AND RESEARCH

1. Apply Vasopressors (for Hypotension That Does Not Respond to Initial Fluid Resuscitation) to Maintain a Mean Arterial Pressure (MAP) 65 mm Hg

VASOPRESSOR AND INOTROPE USAGE IN SHOCK

Double pumping of intravenous vasoactive drugs in the critical care setting.

Inotrope and Vasopressor Therapy of Septic Shock

Inpatient Heart Failure Management: Risks & Benefits

The Sepsis Puzzle: Identification, Monitoring and Early Goal Directed Therapy

ACLS PHARMACOLOGY 2011 Guidelines

ANNE ARUNDEL MEDICAL CENTER CRITICAL CARE MEDICATION MANUAL DEPARTMENT OF NURSING AND PHARMACY. Guidelines for Use of Intravenous Isoproterenol

Management of septic shock with a norepinephrine-based haemodynamic algorithm

Norepinephrine supplemented with dobutamine or epinephrine for the cardiovascular support of patients with septic shock

Chapter 16. Learning Objectives. Learning Objectives 9/11/2012. Shock. Explain difference between compensated and uncompensated shock

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

ADRENERGIC RECEPTOR AGONIST,CLASSIFICATION AND MECHANISM OF ACTION.

Sepsis: Identification and Treatment

STAGES OF SHOCK. IRREVERSIBLE SHOCK Heart deteriorates until it can no longer pump and death occurs.

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, NP Education Specialist LRM Consulting Nashville, TN

Chapter 2 Vasopressors and Inotropes

Evidence-Based Management of Severe Sepsis and Septic Shock

Riociguat Clinical Trial Program

Optimal fluid therapy in Eric Hoste Department of Intensive Care Medicine Ghent University Hospital Ghent University

Journal reading. Method. Introduction. Measurement. Supervisor: F1 徐 英 洲 Presentor:R1 劉 邦 民

The 5 Most Important EMS Articles EAGLES 2014

Adrenergic agonists. R. A. Nimmi Dilsha Department of pharmacy Faculty of Health Sciences The Open University of Sri Lanka

Advantages and disadvantages of CRRT in ARF patients. Norbert Lameire Renal Division University Hospital Ghent, Belgium

Pharmacology - Problem Drill 06: Autonomic Pharmacology - Adrenergic System

Atrial Fibrillation Management Across the Spectrum of Illness

SE5h, Sepsis Education.pdf. Surviving Sepsis

Epinephrine in CPR. The 5 Most Important EMS Articles EAGLES Epi vs No-Epi Take Homes 2/28/2014. VF/VT (1990 Pairs) Epi vs No-Epi

Treatment of cardiogenic shock

Sepsis Reassess patient Monitor and maintain respiratory/ hemodynamic status

ACLS Cardiac Arrest Algorithm Neumar, R. W. et al. Circulation 2010;122:S729-S767

Safe Zone: CV PIP < 26; HFOV: MAP < 16; HFJV: MAP < 16 Dopamine infusion up to 20 mcg/kg/min Epinephrine infusion up to 0.1 mcg /kg/min.

Rome Disclosure. The speaker cooperates with the following companies. BMeye Drager-Siemens Pulsion.

Update on Small Animal Cardiopulmonary Resuscitation (CPR)- is anything new?

Patient Schematic. Perkins GD et al The Lancet, 385, 2015,

Acknowledgements. PAH in Children: Natural History. The Sildenafil Saga

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

ESCMID Online Lecture Library. by author

Adding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT

Subject: Severe Sepsis/Septic Shock Published Date: August 9, 2013 Scope: Hospital Wide Original Creation Date: August 9, 2013

Drugs affecting the autonomic nervous system. Objectives. Autonomic Nervous System (ANS) 12/23/2014

Cardiac Arrest VF/Pulseless VT Learning Station Checklist

Pressure Ulcers in the ICU Incidence, Risk Factors & Prevention

Aktuelle Literatur aus der Notfallmedizin

BUNDLES IN 2013: SURVIVING SEPSIS CAMPAIGN

DIPHENHYDRAMINE (Benadryl)

Decreasing Sepsis Mortality at the University of Colorado Hospital

International Guidelines for Management of Severe Sepsis and Septic Shock

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

PREPARATIONS: Adrenaline 1mg in 1ml (1:1000) Adrenaline 100micrograms in 1ml (1:10,000)

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

New Approaches for Prehospital Cardiac Arrest Management 2010 NCEMSF Conference

Inpatient Code Sepsis March Update. Sarah Prebil

Sign up to receive ATOTW weekly

MEDICATIONS USED IN ADULT CODE BLUE EMERGENCIES. Source: ACLS Provider Manual. American Heart Association. 2001, Updated 2003.

ADRENERGIC AND ANTI-ADRENERGIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

Adrenergic receptors lec 9, part 2. 16/10/2014 Dr. Laila M. Matalqah Rama Kamal Ali Treany

Multi-Organ Dysfunction Syndrome Lesson Description Mitch Taylor

1. The potential sites of action for sympathomimetics and the difference between a direct and indirect acting agonist.

Paddy McMaster Consultant in Paediatric Intensive Care University Hospital of North Staffordshire Stoke on Trent UK

U.S. Food and Drug Administration

Telemedicine Resuscitation & Arrest Trials (TreAT)

Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)

New Anticoagulants- Dabigatran/Rivaroxaban

Intravenous Infusions

Recommendations: Other Supportive Therapy of Severe Sepsis*

NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #78. Enteral Feeding and Vasoactive Agents: Suggested Guidelines for Clinicians

Acute heart failure may be de novo or it may be a decompensation of chronic heart failure.

John Gasman, MD Alec Jamieson, RN, MSN Kim Clifforth, RN, BSN, MSN, CNS Thomas T. Lam, MD. June 18, 2013

Sudden Cardiac Arrest- Focusing on the Unsolved Problems

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

Paediatric Intensive Care unit Nursing Procedure: The Administration of Inotropes

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Transcription:

VASOPRESSOR AGENTS IN SEPTIC SHOCK Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles President European Society of Intensive Care Medicine

Even non sustained (<60min) hypotension is associated with a poor outcome and should not be neglected Marchick et al ICM 35:1261;2009 700 pts with sepsis at ED OR 2.7 (1.2-5.8)

Time spent with hypotension is associated with a poor outcome Dunser M et al ICM 35:1225;2009 274 pts with sepsis in ICU

High doses of vasopressors used to reach a given pressure levels are deleterious Dunser et al Crit Care 13:R181;2009 MAP quartiles: I 70-74.3 II 74.3-77.8 III 77.8-82.1 IV 92.1-99.7 290 pts with septic shock VP for MAP>70 mmhg

Both severity and duration of hypotension are associated with poor outcome. It sounds thus reasonable to try to correct hypotension without delay. Which blood pressure target? Which agent should be used?

Does correction of hypotension with vasopressors affect tissue perfusion? DDB USI

Correction of hypotension improves urine output and renal function in septic patients Albanese et al Chest 126:534;2004 MAP 50 => 78 mmhg Patients with septic shock (n=14) DDB USI

MAP 54 => 77 mmhg Correction of hypotension improves microvascular reactivity (NIRS) Georger et al ICM 36:1882;2010

Which blood pressure target? DDB USI

PRESSURE GOAL? LeDoux et al CCM 28:2729;2000

High vs Low MAP? 65-70 VS 80-85 mmhg Asfar P et al NEJM 2014 But lower incidence of AKI with high MAP in previously hypertensive patients Higher rate of arrhythmias and AMI in high MAP 798 pts septic shock

High vs Low MAP? 73-75 65-70 VS 80-85 mmhg Asfar P et al NEJM 2014 Target 65-70 798 pts septic shock

High variablity in response to increase in MAP Renal Doppler Deruddre et al ICM 33:1557;2007 11 pts septic shock

Impact of MAP/NE on microvascular perfusion Dubin et al Crit Care 2009

VASOPRESSOR SUPPORT Adrenergic agents: Dopamine Norepinephrine Epinephrine Phenylephrine

ADRENERGIC AGENTS ALPHA BETA DOPA DOPAMINE ++ +(+) + NOREPINPHRINE ++++ + - EPINEPHRINE ++++ ++++ - PHENYLEPHRINE ++++ - -

ADRENERGIC AGENTS Alpha + vasopressor effect - increase in afterload, decrease in regional blood flows Beta + inotropic effect, increase in regional blood flows - arrhythmias, immunodepression, metabolic effects Dopa + increase in renal and splanchnic blood flow (?) - alteration hypothalamo-pituitary axis

Hemodynamic effects of vasopressors CO EPINEPHRINE DOPA NOREPINEPHRINE PHENYLEPHRINE MAP

Rats CLP Ducrocq N et al Anesthesiology 116:1083;2012

Change in CI (%) 16 14 12 10 8 6 4 2 0 Schreuder et al Chest 95:1282;1989 DOPA NOREPI

De Backer et al CCM 31:1659;2003 CARDIAC INDEX L/min.M² 7 6 **$$ 5 4 3 2 DOPA NOREPI EPI MAP constant

DOPAMINE vs NOREPINEPHRINE Effects on regional blood flow?

Correction of hypotension improves urine output and renal function in septic patients Albanese et al Chest 126:534;2004 MAP 50 => 78 mmhg Patients with septic shock (n=14) DDB USI

Effects of dopamine, norepnephrine and epinephrine in patients with septic shock De Backer et al CCM 31:1659;2003

Beck et al Crit Care 4:485;2004 But these agents are not only correcting blood pressure..

NOREPINEPHRINE vs EPINEPHRINE Background

Dose dependent stimulation of beta adrenergic receptor with EPI VO2 CO Dose

Lactate mm/l 6 5 Metabolic effects of epinephrine Levy B, Intensive Care Med 1997, 23; 282-287. * * 4 3 2 1 0 0 1 6 12 Epinephrine Norepinephrine + dobutamine Hours DDB USI

280 pts Myburgh et al ICM 34:2226;2008

Annane et al Lancet 370:676;2007 MAP 330 pts septic shock ph Lactate

Myburgh et al ICM 34:2226;2008 280 pts

Levy B et al CCM 2011 30 pts cardiogenic shock Norepi + dobu VS Epi

EPI vs NOREPI (+-DOBU) Annane et al Lancet 370:676;2007 330 pts septic shock

DOPAMINE vs NOREPINEPHRINE

SOAP study DOPAMINE vs NOREPINEPHRINE 1058 pts in shock (any cause) Sakr et al CCM 34:589;2006 No dopamine n=683 Dopamine n=375 Log Rank = 4.6; p = 0.032

SOAP study DOPAMINE vs NOREPINEPHRINE 1058 pts in shock Multivariate logitstic regression Sakr et al CCM 34:589;2006 Coefficient Mean, SE Odds ratio (95 % CI) p value Mean SOFA score 0.424 0.031 1.528 (1.437-1.624) <0.001 Mean fluid balance 0.348 0.059 1.416 (1.261-1.591) <0.001 Medical admission 0.857 0.167 2.356 (1.697-3.271) <0.001 Age 0.018 0.005 1.018 (1.007-1.029) 0.001 Dopamine administration 0.514 0.172 1.673 (1.193-2.345) 0.003 Cancer 0.716 0.243 2.046 (1.270-3.297) 0.003

SACiUCI study DOPAMINE vs NOREPINEPHRINE Povoa et al CCM 37:410;2009 Dopamine Norepi 458 patients septic shock

Prospective Randomized Double blind Multicenter

Administration of vasoactive drugs: Open label NE Study drug (DOPA vs NE) Dose increments (study drug)*: 2 mcg/kg.min for DOPA 0.04 mcg/kg.min for NE Maximal dose (study drug)*: 20 mcg/kg.min for DOPA 0.19 mcg/kg.min for NE * Calculated after Marik et al JAMA 272:1354;1994 De Backer et al CCM 31:1659;2003

De Backer et al NEJM 362: 779; 2010

Comparison of dopamine and norepinephrine as the first vasoactive agent in the management of shock De Backer et al NEJM 362: 779; 2010 Type of shock DOPA NOREPI Septic 542 (63) 502 (61) Cardiogenic 135 (16) 145 (18) Hypovolemic 138 (16) 125 (15) other 48 (6) 44 (5) p = 0.707

Norepinephrine vs Dopamine in shock (SOAP investigators) De Backer et al NEJM 362: 779; 2010 N = 1679 * p<0.05

Comparison of dopamine and norepinephrine as the first vasoactive agent in the management of shock De Backer et al NEJM 362: 779; 2010 * p<0.05

Cardiac index De Backer et al NEJM 362: 779; 2010

Lactate De Backer et al NEJM 362: 779; 2010

Norepinephrine vs Dopamine in shock (SOAP investigators) De Backer et al NEJM 362: 779; 2010

Comparison of dopamine and norepinephrine as the first vasoactive agent in the management of shock De Backer et al NEJM 362: 779; 2010 Septic (1044) / Cardiogenic (280) / hypovolemic (263)

Comparison of dopamine and norepinephrine as the first vasoactive agent in the management of shock Arrhythmias N= 200 150 P < 0.001 De Backer et al NEJM 362: 779; 2010 100 DOPA NOREPI 50 0 Atr fib Ventr tachyc Ventr fib

Other trials??

Septic shock n=252 / Single centre Patel et al Shock 33: 375; 2010

Arrhythmias N= 40 30 P < 0.001 Patel et al Shock 33: 375; 2010 20 DOPA NOREPI 10 0 Atr tachyc Atr fib Septic shock n=252 / Single centre Ventr tachyc

Dopamine vs norepinephrine in septic shock A meta-analysis De Backer et al CCM 40:725:2012 Norepi better

VASOPRESSOR SUPPORT Adrenergic agents: Dopamine Norepinephrine Epinephrine Non-Adrenergic agents: Vasopressin (NO inhibition)

VASOPRESSIN Vasopressin deficiency in septic shock Landry et al Circ 95:1122;1997 DDB USI

VASOPRESSIN IN PATIENTS WITH SEPTIC SHOCK Vasopressin 0.03-0.05 u/min in 5 patients with septic shock Landry et al CCM 25:1279;1997 Mean arterial Pressure mmhg 100 95 90 85 80 75 70 65 60 55 50 BASE AVP P<0.01 PAT 1 PAT 2 PAT 3 PAT 4 PAT 5 DDB USI

The pro side increases blood pressure spares vasopressors improves renal function (?) less arrhythmias The con side high doses are detrimental decreases cardiac output promotes gut ischemia? impairs liver function? Impact on platelets?

VASST Russell et al NEJM 358:877;2008 802 septic shock pts

VASST Russell et al NEJM 358:877;2008 Mortality (%) according to severity at baseline 60 50 40 30 20 10 0 28 day 90 day NOREPI VP 50 45 40 35 30 25 20 15 10 5 0 p<0.05 28 day 90 day p<0.05 More severe n= 400 (NE > 15 mcg/min) Less severe n= 378 (NE < 15 mcg/min)

Vasopressin vs Noradrenaline as Initial therapy in Septic Shock (VANISH): a randomised controlled trial. Gordon A et al A double-blind parallel group factorial (2x2) randomised controlled trial of vasopressin (up to 0.06 u/min) vs noradrenaline, and hydrocortisone vs placebo in septic shock. 400 pts To be presented at ESICM LIVES 2015

LNNMA IN PATIENTS WITH SEPTIC SHOCK Lopez et al CCM 32:21;2004 Placebo LNNMA DDB USI

VASOPRESSOR SUPPORT IN SHOCK Correction of hypotension (MAP ~65 mmhg) MAP higher than 65-70 mmhg do not seem to further improve tissue perfusion Adrenergic agents as first line agent, with norepinephrine as the 1st choice agent Vasopressin appears to be promising in septic shock DDB USI

Thank you